Search academic texts

Information × Registration Number 0211U006240, 0106U005544 , R & D reports Title The study of immunomodulating and anticancer action of recombinant beta-defensin-2 popup.stage_title Head Pogrebnoy Petro Vasylievich, Registration Date 02-03-2011 Organization R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology popup.description2 We have obtained recombinant mouse beta-defensin-2 (mBD-2) cloned in bacterial cells as a fusion protein with glutathione-S-transferase (GST), and polyclonal anti-mBD-2-antibodies. Using model system (Lewis lung carcinoma cells, 3LL, transfected with pсDNA3-Igk-mBD-2 or pсDNA3-mBD-2 vectors), we have found the presence of reverse correlation between expression level of mBD-2 mRNA and and proliferation rate of 3LL cells. It has been shown that introduction of vitamin D3 in vivo activates mBD-2 expression in normal mouse lung cells. Application of protein anticancer vaccine composed from recombinant mBD-2 and 3LL cell lyzate at therapeutic and prophylactic regimens has shown that antitumor and antimetastatic effects of vaccinations could be achieved upon its combination of systemic administration of VD3 and metronomic administration of cyclophosphane. We have designed and constructed also experimental DNA vaccine coding sequences of mBD-2 and murine mucin-1 genes. We have documented positive clinical effect of vaccination with the use of this DNA-mBD-2-Muc1vaccine combined with VD3 treatment, reflected in significant antimetastatic effect and elevation of average life span of vaccinated tumor-bearing animals. Immunologic studies evidence about activation of cellular immunity, but not humoral immune response, in animals treated with DNA-vaccine combined with VD3 administration. Product Description popup.authors Єфанова Ольга Леонідівна Глушко Наталія Віталіївна Журавель Олена Валентинівна Солдаткіна Марія Олександрівна Шестакова Тетяна Сергіївна popup.nrat_date 2020-04-02 Close